Consistency of Primary Brain Tumor Diagnoses and Codes in Cancer Surveillance Systems

Castillo, Monette S.; Davis, Faith G.; Surawicz, Tanya; Bruner, Janet M.; Bigner, Sandra H.; Coons, Stephen Joel; Bigner, Darell D.

doi:10.1159/000073980

Cited by 36 publications

(25 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a recent assessment of patients with brain tumors from the Connecticut Tumor Registry (a SEER site), absolute concordance rates of 49 -81% were observed for the pathology review, with mixed tumors having relatively high discordance rates relative to pathology review. 31 Numerous other retrospective studies have presented survival rates for patients with low-grade gliomas by surgical resection extent (gross total, subtotal, or biopsy); however, they are difficult to compare with the current data, because most of those studies did not present estimates by specific age or histologic groups, and nor did they provide confidence interval estimation for risk estimates. Furthermore, many of the previous studies included subtypes of patients that were not included in the current study, such as patients with diagnoses of epilepsy.…”

Section: Discussionmentioning

confidence: 85%

“…Eligible study participants for this analysis included all patients who underwent resection within the intraoperative MRI operating suite at BWH in Boston who were diagnosed with a unifocal, histologically confirmed, low-grade (Grade 1 or 2), supratentorial, nonoptic pathway glioma between January 1, 1997 and January 31,2003, and who had a minimum of 1 year of follow-up (n ϭ 156 patients). The histologic subtypes included in this analysis were astrocytoma (International Classification of Diseases for Oncology [ICD-O] codes 9400, 9410, and 9420), mixed glioma (ICD-O code 9382), and oligodendroglioma (ICD-O code 9450).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Survival rates in patients with low‐grade glioma after intraoperative magnetic resonance image guidance

Claus

Horlacher

Hsu

et al. 2005

Cancer

430

191

View full text Add to dashboard Cite

Background We sought to examine hearing loss in a group from the Royal Australian Air Force who undertook fuel tank maintenance on F‐111 aircraft, with exposure to formulations containing ototoxins, relative to two different comparison groups. Methods Using pure‐tone audiometry, hearing thresholds were assessed in 614 exposed personnel, 513 technical‐trade comparisons (different base, same job), and 403 non‐technical comparisons (same base, different job). We calculated percentage loss of hearing (PLH) and used regression models to examine whether there was an association between PLH and F‐111 fuel tank maintenance, adjusting for possible confounders. In addition, the difference between the observed hearing thresholds and the expected thresholds based on an otologically normal population (ISO‐7029‐2003) was determined. Results The PLH ranged from nil to 96 (median 1.5, quartiles 0.3, 5.5). A logistic regression model showed no statistically significant difference in PLH among the three exposure groups (exposed vs. non‐technical controls 1.1: 95% CI 0.7, 2.0 and exposed vs. technical OR 0.9: 95% CI 0.6, 1.3). The model also highlighted a number of other risk factors for PLH including age, tinnitus, smoking, depression, and use of depression medications. However, at all eight frequencies measured, all populations had lower than expected hearing thresholds based on published ISO‐7029 medians. Conclusions Although there was no difference in PLH between the three exposure groups, the study did reveal a high degree of hearing loss between the 3 groups and a normal population. Am. J. Ind. Med. 53:1159–1169, 2010. © 2010 Wiley‐Liss, Inc.

show abstract

Section: Discussionmentioning

confidence: 85%

Section: Methodsmentioning

confidence: 99%

Survival rates in patients with low‐grade glioma after intraoperative magnetic resonance image guidance

Claus

Horlacher

Hsu

et al. 2005

Cancer

430

191

View full text Add to dashboard Cite

show abstract

“…However, studies examining other cancers have demonstrated an acceptable rate of concordance between a patient's pathology and its coded representation in a cancer registry. 5 Despite these limitations, these data add considerably to our understanding of cerebellar low-grade astrocytoma in adults.…”

Section: Discussionmentioning

confidence: 99%

Improved survival in the largest national cohort of adults with cerebellar versus supratentorial low-grade astrocytomas

Bagley¹,

Babu²,

Friedman³

et al. 2013

FOC

View full text Add to dashboard Cite

Object Low-grade gliomas (LGGs) are indolent tumors that have the potential to dedifferentiate into malignant high-grade tumors. Recent studies have demonstrated that cerebellar low-grade tumors have a better prognosis than supratentorial tumors, although no study has focused on the risk factors for poor prognosis in cerebellar LGGs in adults. The authors of the current study aimed to address both of these concerns by using a large cohort derived from a national cancer registry and a smaller cohort derived from their institution's experience. Methods Adults with diagnosed Grade I and Grade II gliomas of the cerebellum were identified in the Surveillance, Epidemiology, and End Results (SEER) database. Multivariate Cox proportional hazard models were used to predict rates of survival, and the log-rank test was applied to evaluate differences in Kaplan-Meier survival curves. An institutional cohort was created by isolating all patients whose surgical pathology revealed an LGG of the cerebellum. Excluded from analysis were patients in whom a glioma was first diagnosed under the age of 18 years and those whose tumors could not be definitively determined to arise from the cerebellum. Results Data from the local cohort (11 patients) demonstrated that the most common presenting symptom was headache, which occurred in more than 70% of the cohort. Approximately half of the patients in this cohort had symptomatic improvement after treatment. Results from the SEER cohort (166 patients) revealed that adults with Grade I gliomas were slightly younger than those with Grade II tumors (p < 0.01), but no other demographic differences were observed. Patients with Grade I tumors were twice as likely to undergo gross-total resection (54% vs 21%), and those with Grade II gliomas were much more likely to receive postoperative radiation (3% vs 48%). Five-year survival was greater in the patients with Grade I gliomas than in those with Grade II lesions (91% vs 70%). Multivariate analysis revealed that an age ≥ 40 years (HR 7.30, 95% CI 3.55–15.0, p < 0.0001) and Grade II tumors (HR 2.76, 95% CI 1.12–6.84, p = 0.028) were risk factors for death, whereas female sex was protective (HR 0.28, 95% CI 0.14–0.59, p < 0.001). Log-rank tests revealed that a cerebellar location was protective (p < 0.0001), but this relationship was only true for Grade II tumors (p < 0.0001). Survival in patients with Grade I gliomas was not different based on the various lesion locations (p = 0.21). Conclusions Taken together, adults with cerebellar WHO Grade I and II astrocytomas have a much more favorable survival curve than those with similar supratentorial tumors. Research demonstrates that the primary driver of this phenomenon is the improved survival in patients with cerebellar Grade II gliomas.

show abstract

“…Two independent statistical methods were used to produce a model that best classified biopsies in the training data set. The results showed conclusively that protein patterns could readily distinguish between tumor and nontumor tissues, including mapping to individual tumor grades and comparing favorably to studies of interclass observer variability in pathology and neuropathology (11,12). The full data set of 108 glioma patients was then evaluated, averaged by patient, to identify biomarker patterns that correlate to patient survival trends.…”

Section: Protein Signatures In Gliomasmentioning

confidence: 95%

Deciphering Protein Molecular Signatures in Cancer Tissues to Aid in Diagnosis, Prognosis, and Therapy

Caprioli

2005

Cancer Research

View full text Add to dashboard Cite

Protein signatures in disease, a portion of the protein complement of cells that directly reflects disease related changes, provide a unique data set that may be correlated with or be an aid to more effective diagnosis, prognosis, and response to therapy. A recent article in this Journal from the author's laboratory described the protein analysis of glioma tissue and the discovery of protein signatures for assessing the stage of disease as well as their correlation with patient survival. This investigation used direct proteomic analysis of glioma biopsies, the discovery of molecular signatures for stage and outcome, and identification of specific proteins of this signature group. This minireview discusses the background and present state of the technology used in this work and the role that direct tissue analysis can play in the discovery of high-quality protein signatures. (Cancer Res 2005; 65(23): 10642-5)

show abstract

Consistency of Primary Brain Tumor Diagnoses and Codes in Cancer Surveillance Systems

Cited by 36 publications

References 9 publications

Survival rates in patients with low‐grade glioma after intraoperative magnetic resonance image guidance

Survival rates in patients with low‐grade glioma after intraoperative magnetic resonance image guidance

Improved survival in the largest national cohort of adults with cerebellar versus supratentorial low-grade astrocytomas

Deciphering Protein Molecular Signatures in Cancer Tissues to Aid in Diagnosis, Prognosis, and Therapy

Contact Info

Product

Resources

About